GLP-1 Drugs for PCOS: Semaglutide, Tirzepatide and What Happens When You Stop

What do GLP-1 drugs actually do in the body?

GLP-1 receptor agonists mimic a gut hormone your body already makes after eating, and that mimicry — a biochemical signal, not a change in resolve — is the entire mechanism. Semaglutide binds the same receptor as your natural GLP-1, which slows how fast food leaves your stomach, prompts insulin release only when blood sugar is already elevated (which is why it carries a lower hypoglycemia risk than older insulin-boosting drugs), and acts on appetite centers in the hypothalamus to reduce hunger signaling. Tirzepatide does the same thing at the GLP-1 receptor and adds a second action at the GIP receptor. The 2023 review of tirzepatide’s potential in PCOS notes that this second receptor is the proposed reason tirzepatide may produce less severe gastrointestinal side effects than GLP-1-only drugs — a real adherence problem, since nausea and vomiting are the most common reason people stop either drug early.

None of this mechanism is specific to PCOS. It’s the same pathway whether the person taking it has type 2 diabetes, general obesity, or PCOS with insulin resistance — which is exactly why the question of PCOS-specific evidence, rather than borrowed mechanism, matters so much for what follows.

Is there PCOS-specific evidence for semaglutide, or is it all extrapolated?

Semaglutide has real, if limited, PCOS-specific trial data — more than most GLP-1 coverage for PCOS implies, and more than tirzepatide currently has. A 2025 randomized, controlled, open-label trial of 100 overweight or obese women with PCOS compared metformin alone against metformin plus weekly semaglutide for 16 weeks. The combination group lost an average of 6.09 kg versus 2.25 kg with metformin alone, alongside greater improvements in testosterone, visceral adiposity, and inflammatory markers (CRP). In an extension phase, the semaglutide group also had a higher natural pregnancy rate over the following 24 weeks — 35% versus 15% with metformin alone. That is one trial, not a body of evidence, but it’s a real, PCOS-specific, randomized comparison — not an inference borrowed from a different population.

Tirzepatide has no such trial. A 2023 review lays out the mechanistic case for why it might help PCOS — it acts on the same GLP-1 pathway as semaglutide, plus a second receptor (GIP), which may reduce the gastrointestinal side effects that limit adherence to GLP-1-only drugs — but the review is explicit that this is hypothesis, not trial result. Every number attached to tirzepatide’s weight or metabolic effects, including the ones in the next section, comes from general obesity or type 2 diabetes trials that did not screen for or report on PCOS.

What does semaglutide vs. metformin actually look like, side by side?

The 16-week trial above is the clearest head-to-head PCOS data available, and it’s worth reading in full rather than as a soundbite about “6 kg more.”

Two limits matter here. The dose used was 1 mg weekly — well below the 2.4 mg ceiling studied for weight loss in the general population — so this trial doesn’t tell you what a higher dose would do in PCOS specifically. And it ran 16 weeks, which is long enough to show a direction but far short of the multi-year timeline most people actually stay on these drugs. Both are reasons to treat this as a genuine, encouraging first data point — not a settled answer for dosing or duration.

What happens to the weight after you stop a GLP-1 drug?

Roughly two-thirds of lost weight comes back within a year of stopping semaglutide, based on the best long-term data available — an extension of the general-population trial, not a PCOS-specific one. The STEP 1 trial extension followed 327 participants who had lost an average 17.3% of body weight over 68 weeks on semaglutide. One year after stopping the drug — and the accompanying lifestyle program — participants regained 11.6 percentage points of that loss, landing at a net 5.6% below their starting weight, down from the 17.3% they’d reached on treatment. The comparison group that had been on placebo the whole time showed almost no change either way. Cardiometabolic improvements — blood pressure, lipids, glucose markers — reverted toward baseline on roughly the same timeline as the weight.

No equivalent stopping study exists for tirzepatide or for PCOS specifically, so treat the STEP 1 numbers as the best available estimate of the pattern, not a PCOS-confirmed one.

Does semaglutide or tirzepatide cause muscle loss, and does that matter?

Roughly a quarter of the weight lost on tirzepatide is lean mass, not fat, according to a DXA substudy of the pivotal obesity trial. The SURMOUNT-1 body-composition substudy scanned 160 participants and found that of the total weight lost on tirzepatide, about 75% was fat mass and 25% was lean mass — proportions that held up whether someone lost a little weight or a lot. Fat mass fell 33.9% and lean mass fell 10.9% over 72 weeks, compared with 8.2% and 2.6% respectively on placebo. That 25% lean-mass share is a meaningfully large slice of a large total weight loss, and in muscle terms it’s not trivial.

This is where resistance training and protein intake earn a place in the conversation, not as an optional add-on but as the direct counter to a documented drug effect. A small case series tracking patients who paired GLP-1 therapy with structured resistance training and protein intake above roughly 1.6 g per kilogram of fat-free mass found much better preservation of lean tissue than the population-level SURMOUNT-1 proportions above — a promising early signal, not proof, since case series lack a comparison group. The direction is consistent with basic physiology: muscle responds to mechanical loading and protein availability regardless of what’s driving the calorie deficit, and a GLP-1-driven deficit doesn’t exempt anyone from that. See strength training for PCOS for a starting program built around the same insulin mechanism these drugs are working on.

Who should not take a GLP-1 drug — the contraindications

A personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 rules out GLP-1 receptor agonists entirely — this is an absolute contraindication, not a relative one requiring a judgment call. A systematic literature review of semaglutide’s thyroid safety profile found that while trials to date have not confirmed a causal link to thyroid cancer in the general population, the rodent-model signal behind the original warning is the reason this contraindication has not been lifted, and it applies regardless of how compelling the metabolic case looks otherwise.

Beyond that, a personal history of pancreatitis is a relative contraindication requiring a specific risk conversation with a prescriber before starting, and pregnancy is a reason to stop rather than start — GLP-1 drugs are not studied for safety in pregnancy, which matters specifically in PCOS given how many people start one of these drugs while also actively trying to conceive. If a semaglutide-assisted pregnancy is the goal, as in the trial in Table 1, the sequencing — and the point at which to stop the drug — is a conversation for a prescriber, not a self-directed decision.

What is the compounded-semaglutide risk, specifically?

A case series reported to a regional poison control center described three patients who suffered adverse drug events after obtaining semaglutide from compounding pharmacies or a med spa, and two of the three had self-administered doses roughly 10 times higher than intended — the clearest documented evidence that compounded semaglutide, sold outside the FDA-approved supply chain and often without the safety mechanisms built into manufactured pens, carries a real, quantified overdose risk. This happens because compounded vials require the patient to draw up their own dose with a syringe rather than using a pre-set pen, and dosing units (milligrams, milliliters, “units”) got confused in the process. All three patients experienced days of nausea, vomiting and abdominal pain; one required IV fluids.

This isn’t a case against GLP-1 drugs — it’s a case against the unregulated supply chain some people use to access them more cheaply or without a prescription. A prescription for the manufactured, FDA-approved product, dispensed with the calibrated pen it was designed for, doesn’t carry this specific risk.

Ozempic vs. metformin for PCOS — which comes first?

The only head-to-head PCOS trial available tested semaglutide added to metformin over 16 weeks, not semaglutide instead of it, and found the combination outperformed metformin alone on weight, hormones and pregnancy rate. Metformin remains the more established option for PCOS’s underlying insulin resistance, with a trial history that runs decades longer — see metformin for PCOS for the mechanism and dosing conversation. That’s a meaningfully different question from “which one should I start with” — the trial doesn’t establish semaglutide as a metformin replacement, only as something that added benefit on top of it in this specific 16-week window. For most people, metformin’s much longer track record makes it the reasonable starting conversation, with semaglutide or tirzepatide raised as an addition if weight and metabolic markers aren’t moving enough on metformin alone — a sequencing question to bring to a prescriber, not a race to the newer drug. A different, older option sometimes comes up in the same conversation: phentermine, a short-term appetite suppressant that works through neither of the mechanisms above.

You may see PCOS referred to as polyendocrine metabolic ovarian syndrome (PMOS), after a 2026 global consensus of more than 50 medical organisations renamed it. Nothing about the drug mechanisms or trial data above changes under either name — this article uses PCOS because that’s still what most readers search.

This is one entry in the site’s weight-loss section, which treats weight as a metabolic marker tied to insulin, androgens and cardiometabolic risk — not a number a drug is meant to force down for its own sake.

Where this will not work for you

If your PCOS presents lean, with normal or low body weight and androgen excess as the dominant feature, none of the trials above apply to you — every one of them enrolled women who were overweight or obese, and GLP-1 drugs are approved and studied for weight-related metabolic indications, not as a treatment for androgen excess on its own. If your main goal is fertility and you are not also managing a weight-related metabolic picture, the trial in Table 1 doesn’t tell you whether semaglutide would help your specific case; it tested a population selected for excess weight. And if you have any of the contraindications above, this entire drug class is off the table regardless of how well-suited the metabolic profile otherwise looks.

Your next step

If you’re overweight or obese with PCOS and metformin alone hasn’t moved your weight or metabolic markers, bring three things to your next appointment: your personal and family thyroid and pancreatitis history, your current fertility plans and timeline, and a direct question — “Is a GLP-1 medication appropriate for me, and if I start one, what does stopping it eventually look like?” That last question, given the STEP 1 data above, deserves an answer before you start, not after.